Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy

European Heart Journal
Rajeev K PathakRajat Deo

Abstract

Sudden cardiac death (SCD) accounts for approximately one-third of all deaths among patients with non-ischaemic cardiomyopathy (NICM). Implantable cardioverter-defibrillator (ICD) therapy has been the primary intervention for managing individuals at high risk for SCD. However, individual ICD trials in the NICM population have failed to demonstrate a mortality benefit with prophylactic ICD implantation. Current guidelines recommend ICD implantation in NICM patients with symptomatic heart failure and a left ventricular ≤35% and are based on meta-analyses of multiple trials that span three decades and include the recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischaemic Heart Failure on Mortality (DANISH) trial. These pooled analyses report a significant reduction in all-cause mortality with ICD implantation compared with medical therapy alone. In addition, each of these trials has demonstrated consistently a reduction in the risk of SCD compared with medical therapy alone. As a result, a refined approach of risk stratification that selects patients at the highest risk for SCD may lead to a significant improvement in ICD efficacy. In this clinical review, we first discuss the evolution of clinical trials th...Continue Reading

References

Sep 1, 1989·Journal of the American College of Cardiology·A GradmanS Goldstein
Feb 1, 1996·European Heart Journal·M GalinierJ P Bounhoure
Mar 17, 1999·Circulation·J M PastoreD S Rosenbaum
Aug 8, 2002·Pacing and Clinical Electrophysiology : PACE·Henry H Hsia, Francis E Marchlinski
Mar 12, 2003·Journal of the American College of Cardiology·Matthew R G TaylorUNKNOWN Familial Dilated Cardiomyopathy Registry Research Group
May 21, 2004·The New England Journal of Medicine·Michael R BristowUNKNOWN Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators
May 21, 2004·The New England Journal of Medicine·Alan KadishUNKNOWN Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators
Jun 15, 2004·Journal of the American College of Cardiology·James C C MoonDudley J Pennell
Nov 20, 2004·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jop H van BerloYigal M Pinto
Dec 16, 2004·JAMA : the Journal of the American Medical Association·Akshay S DesaiKenneth L Baughman
Jan 22, 2005·The New England Journal of Medicine·Gust H BardyUNKNOWN Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators
Jul 5, 2005·Journal of the American College of Cardiology·Anil K GehiJ Anthony Gomes
Oct 29, 2005·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Anselma IntiniAlbert L Waldo
Jan 13, 2006·The New England Journal of Medicine·Christophe MeuneDenis Duboc
Jul 11, 2007·Circulation·Dariush MozaffarianWayne C Levy
Aug 22, 2007·Annals of Internal Medicine·Justin A EzekowitzFinlay A McAlister
Oct 18, 2008·Journal of the American College of Cardiology·Michele PasottiEloisa Arbustini
Aug 20, 2010·Clinical Genetics·K Y van Spaendonck-ZwartsJ P van Tintelen
Mar 12, 2011·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Haris M HaqqaniFrancis E Marchlinski
Apr 16, 2011·Journal of the American College of Cardiology·Ray E Hershberger, Jill D Siegfried
May 21, 2011·Journal of the American College of Cardiology·William P McNairUNKNOWN Familial Cardiomyopathy Registry Research Group
Feb 2, 2012·Circulation·Rajat Deo, Christine M Albert

❮ Previous
Next ❯

Citations

Aug 16, 2019·Circulation. Cardiovascular Quality and Outcomes·T Jared Bunch
Dec 12, 2018·The Cochrane Database of Systematic Reviews·Mohamad El MohebMarwan Refaat
Dec 13, 2018·PloS One·Barna SzabóNoémi Nyolczas
Nov 17, 2020·Frontiers in Cardiovascular Medicine·Nathan EngstromHayley L Letson
Nov 21, 2020·European Heart Journal·Thomas F Lüscher
Mar 23, 2019·JACC. Clinical Electrophysiology·Zachary LaksmanAndrew D Krahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Karin KraaierPascal F H M van Dessel
Current Treatment Options in Cardiovascular Medicine
Jaydutt B Patel, Bruce A Koplan
© 2022 Meta ULC. All rights reserved